tert-butyl (2R,4S)-4-((tert-butyldimethylsilyl)oxy)-2-(hydroxymethyl)pyrrolidine-1-carboxylate | 134441-72-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: tert-butyl (2R,4S)-4-((tert-butyldimethylsilyl)oxy)-2-(hydroxymethyl)pyrrolidine-1-carboxylate
• 英文别名: tert-butyl (2R,4S)-4-{[tert-butyl(dimethyl)silyl]oxy}-2-(hydroxymethyl)pyrrolidine-1-carboxylate；tert-butyl (2R,4S)-4-[tert-butyl(dimethyl)silyl]oxy-2-(hydroxymethyl)pyrrolidine-1-carboxylate
• CAS: 134441-72-8
• 化学式: C₁₆H₃₃NO₄Si
• 分子量: 331.528
• InChiKey: IIITUHPEBILIQR-OLZOCXBDSA-N

物化性质

• 沸点：
  373.4±27.0 °C(Predicted)
• 密度：
  1.02±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.38
• 重原子数：
  22
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.94
• 拓扑面积：
  59
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  tert-butyl (2R,4S)-4-((tert-butyldimethylsilyl)oxy)-2-(hydroxymethyl)pyrrolidine-1-carboxylate 在 盐酸 、 10% palladium on activated charcoal 、 四丁基氟化铵 、 水 、 氢气 、 三乙基硼氢化锂 、 三乙胺 、 t-butyl ammonium azide 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 甲醇 、 二氯甲烷 、 乙腈 为溶剂， 生成 2,5-二溴-N-[(3R,5S)-1-氰基-5-甲基-3-吡咯烷基]苯磺酰胺
  参考文献：
  名称：

  Discovery of Novel Cyanamide-Based Inhibitors of Cathepsin C

  摘要：

  The discovery of potent and selective cyanamide-based inhibitors of the cysteine protease cathepsin C is detailed. Optimization of the template with regard to plasma stability led to the identification of compound 17, a potent cathepsin C inhibitor with excellent selectivity over other cathepsins and potent in vivo activity in a cigarette smoke mouse model.

  DOI：

  10.1021/ml100212k
• 作为产物：
  描述：

  (2R,4S)-methyl 4-hydroxypyrrolidine-2-carboxylate 在 咪唑 、 锂硼氢 、 三乙胺 作用下， 生成 tert-butyl (2R,4S)-4-((tert-butyldimethylsilyl)oxy)-2-(hydroxymethyl)pyrrolidine-1-carboxylate
  参考文献：
  名称：

  Discovery of Novel Cyanamide-Based Inhibitors of Cathepsin C

  摘要：

  The discovery of potent and selective cyanamide-based inhibitors of the cysteine protease cathepsin C is detailed. Optimization of the template with regard to plasma stability led to the identification of compound 17, a potent cathepsin C inhibitor with excellent selectivity over other cathepsins and potent in vivo activity in a cigarette smoke mouse model.

  DOI：

  10.1021/ml100212k

文献信息

• [EN] QUINAZOLINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER<br/>[FR] DERIVES QUINAZOLINE, UTILISATIONS DE CES DERNIERS DANS LE TRAITEMENT DU CANCER
  申请人：ASTRAZENECA AB

  公开号：WO2004096226A1

  公开（公告）日：2004-11-11

  The invention concerns quinazoline derivatives of the formula: (I); wherein X1, Q1, Z, R1, R2, Y, a and m are as defined in the description, which are erbB tyrosine kinase inhibitors, particularly EGFR tyrosine kinase inhibitors. Also claimed are processes for their preparation; pharmaceutical compositions containing them; and their use as therapeutic agents in the treatment of erbB tyrosine kinase mediated diseases such as cancer.

  该发明涉及喹唑啉衍生物的公式(I)；其中X1、Q1、Z、R1、R2、Y、a和m如描述中定义，它们是erbB酪氨酸激酶抑制剂，特别是EGFR酪氨酸激酶抑制剂。还要求保护它们的制备方法；含有它们的药物组合物；以及它们作为治疗剂在治疗erbB酪氨酸激酶介导的疾病如癌症中的应用。
• [EN] NOVEL CATHEPSIN C INHIBITORS AND THEIR USE<br/>[FR] NOUVEAUX INHIBITEURS DE LA CATHEPSINE C ET LEUR UTILISATION
  申请人：GLAXO GROUP LTD

  公开号：WO2009026197A1

  公开（公告）日：2009-02-26

  The invention is directed to compounds according to Formula (I) wherein R1, R2a, R2b, R2c, R3, and n are defined below, and to pharmaceutically-acceptable salts thereof. They are cathepsin C inhibitors and can be used in the treatment of diseases mediated by the cathepsin C enzyme, such as COPD.

  这项发明涉及到符合以下式（I）的化合物，其中R1、R2a、R2b、R2c、R3和n的定义如下，并且其药用盐。它们是半胱氨酸蛋白酶C抑制剂，可用于治疗由半胱氨酸蛋白酶C酶介导的疾病，如慢性阻塞性肺病。
• Synthesis and hybridization properties of polyamide based nucleic acid analogues incorporating pyrrolidine-derived nucleoamino acids
  作者：Karl-Heinz Altmann、Dieter Hüsken、Bernard Cuenoud、Carlos Garcı́a-Echeverrı́a

  DOI：10.1016/s0960-894x(00)00121-9

  日期：2000.5

  Ndelta-Fmoc protected nucleoamino acids of type I (Base = T, C, A) have been synthesized and employed as building blocks for the construction of novel polyamide based nucleic acid analogues. Homopyrimidine oligomer A binds to complementary RNA with significant affinity and in a sequence-specific fashion, while no binding was observed to complementary DNA.

  已经合成了Ndelta-Fmoc保护的I型核苷酸（碱基= T，C，A），并用作构建新型聚酰胺基核酸类似物的基础。同嘧啶低聚物A以明显的亲和力和序列特异性方式结合互补RNA，而未观察到与互补DNA的结合。
• ADENINE DERIVATIVES
  申请人：Buchstaller Hans-Peter

  公开号：US20100160352A1

  公开（公告）日：2010-06-24

  Novel adenine derivatives of the formula (I), in which R 1 , R 2 , R 3 , X and Y have the meanings indicated in Claim 1 , are HSP90 inhibitors and can be used for the preparation of a medicament for the treatment of diseases in which the inhibition, regulation and/or modulation of HSP90 plays a role.

  新型腺嘌呤衍生物的化学式（I），其中R1、R2、R3、X和Y具有权利要求1中指示的含义，是HSP90抑制剂，可用于制备用于治疗需要HSP90抑制、调节和/或调控的疾病的药物。
• [EN] BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE<br/>[FR] COMPOSÉS CIBLANT BRM ET PROCÉDÉS D'UTILISATION ASSOCIÉS
  申请人：PRELUDE THERAPEUTICS INC

  公开号：WO2022099117A1

  公开（公告）日：2022-05-12

  The present disclosure provides bifunctional compounds comprising a target protein binding moiety and a E3 ubiquitin ligase binding moiety, and associated methods of use.

  本公开提供了一种具有靶蛋白结合基团和E3泛素连接酶结合基团的双功能化合物，以及相关的使用方法。